The Committee for Medicinal Products for Human Use (CHMP) has recommended that Opdivo (nivolumab) be made available for the treatment of adult patients living with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The treatment is specifically designed for patients that have undergone chemotherapy treatments or those living with advanced renal cell carcinoma who have had other treatments.
With the recommendation, the European Commission (EC) will consider approving Opdivo for European Union distribution.
Opdivo, a product of pharmaceutical company Bristol-Myers Squibb, is currently available in Europe as a therapy for patients with advanced melanoma and advanced squamous NSCLC.
Approval for new indications was requested after BMS researchers conducted phase-three studies of Opdivo. Those studies showed that patients treated with Opdivo have increased survival rates compared to patients treated with the current standard of care.
